It is not news that cannabis-based medicines have been used for millennia around the world in the treatment of conditions and diseases such as chronic pain; epilepsy; neuropsychiatric disorders; nausea and vomiting related to chemotherapy; symptoms associated with...
Cannabis
Recent Reform on Brazilian Pharmaceutical Patents Showing Results
In 2021, the Brazilian legislature revoked a controversial article (Article 229-C) in the Brazilian IP Law, ending the participation of ANVISA (the Brazilian FDA) in examining Brazilian patent applications. As discussed below, the revocation of this article was a big...
Brazil in the race to join top cannabis markets?
Brazil is slowly changing its own position towards cannabis-based products in the region, with the background of growing investment in the medicinal benefits of marijuana and having recently provided new rules allowing for the regulated use of medical marijuana...
What to expect from the examination of cannabinoid patent applications after ruling out ANVISA’s interference
Brazilian law # 14,195/21 revoking Article 229-C of the Brazilian IP Law was recently sanctioned by the Presidency, leading to intense debate on how this will affect the examination of patent applications in future. Based on the provisions of said article, any patent...
Brazilian PTO annuls patent for CBD based drug
In a decision published on 27 July, the Brazilian PTO annulled the patent for the drug Myalo, a CBD based medicine marketed by the company Prati-Donaduzzi. As discussed in our previous article on the subject of Patents for Cannabis Products in Brazil, Prati-Donaduzzi...
Cannabis in Brazil: a synopsis of current market
Recent events in Brazil may be seen as further steps in a slowly changing position in the cannabis market across the region. Such change takes place with the background of growing investment in the medicinal benefits of marijuana and other narcotic substances....
The role of ANVISA in cannabis related patents
As mentioned in our previous post on this topic, patent applications for pharmaceutical products or processes must be submitted to ANVISA (The Brazilian Health Surveillance Agency) for prior consent based on a public health analysis. The government lists many...
Patents for cannabis products in Brazil
In a recent post on this topic, we discussed how the slowly changing position toward cannabis-based products in Brazil, with the background of growing investment in the medicinal benefits of marijuana and other narcotic substances. But what is the current position in...
Cannabis products in Brazil: a new agri-business?
Recent events in Brazil may be seen as further steps in a slowly changing position toward cannabis-based products in the region. Such change takes place with the background of growing investment in the medicinal benefits of marijuana and other narcotic substances....
What is the impact of coronavirus on the cannabis industry?
Amid the massive public health crisis caused by the fear of the spread of COVID-19, economies and societies around the world are facing hardship, with entire businesses brought to a sudden halt. It is difficult to predict what markets will look like in the foreseeable...
Brazil Relaxes Its Approach to Cannabis and What It Means to Brand Owners
By Fernanda Quental and Gabriel Sacramento The legalization of the consumption of cannabis and cannabis-derived products in such countries as Canada, Israel, Switzerland, and Uruguay—and several states in the United States—has led to the rapid development of a...